9 citations
,
April 2020 in “The Journal of Urology” 5α-Reductase inhibitors don't cause depression.
These medications for BPH have known risks and may have new side effects.
3 citations
,
August 2020 in “Urology Journal” Using 5-alpha reductase inhibitors may increase the risk of mild depression.
42 citations
,
August 2012 in “Psychoneuroendocrinology” Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.
19 citations
,
October 2018 in “PLOS ONE” 5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
10 citations
,
March 2023 in “Journal of Chemistry” New compounds show promise for treating benign prostate hyperplasia with fewer side effects.
1 citations
,
September 2016 in “Actas Dermo-Sifiliográficas” 5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.
3 citations
,
July 2021 in “Drug Testing and Analysis” 5α-reductase inhibitors can interfere with doping tests by masking banned substances.
78 citations
,
December 2008 in “The Journal of Sexual Medicine” 5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction, but the exact reasons are unclear.
January 2011 in “Medical Recapitulate” 5α-reductase enzyme affects hormone levels, influencing conditions like acne and hair loss.
8 citations
,
July 2021 in “F1000Research” Plant-based compounds might be a promising alternative for prostate cancer treatment with fewer side effects.
21 citations
,
August 1994 in “Clinical endocrinology” 5α-Reductase inhibitors can help treat hair loss, acne, and prostate issues by reducing DHT levels.
January 2021 in “Journal of The European Academy of Dermatology and Venereology” Men with hair loss who take a certain type of medication may experience fewer COVID-19 symptoms.
66 citations
,
April 2017 in “International Journal of Andrology” Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
May 2024 in “European urology focus” Drugs for prostate enlargement and hair loss were not linked to increased risk of depression or suicide.
28 citations
,
May 1986 in “Clinics in endocrinology and metabolism” New compounds may soon be tested to treat excessive hair growth in women.
124 citations
,
January 1996 in “Dermatology” 5 alpha-reductase inhibitors, like finasteride, are used to treat conditions like prostate issues and skin disorders.
46 citations
,
September 2011 in “Journal of Endocrinology” Natural 5α-reduced glucocorticoids might be anti-inflammatory with fewer side effects than current options.
4 citations
,
September 2022 in “Experimental and Сlinical Urology” 5-alpha reductase inhibitors help with benign prostatic hyperplasia but don't cure it, and more research is needed.
6 citations
,
March 2003 in “Archiv Der Pharmazie” Scientists made new substances that can block an enzyme linked to prostate issues and hair loss, with potential for creating a new treatment.
108 citations
,
February 2008 in “The Journal of urology/The journal of urology” Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.
November 2017 in “JAMA internal medicine” Women also use 5α-reductase inhibitors, and their effects differ from men.
26 citations
,
October 2011 in “International Journal of Biological Macromolecules” Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
18 citations
,
March 2020 in “Frontiers in Neuroendocrinology” The enzymes 5α-reductase and 3α/β-hydroxysteroid oxidoreductase help create brain-active substances from progesterone and testosterone, which could be used for treatment, but more research is needed to ensure their safety and effectiveness.
2 citations
,
March 2018 in “Current Opinion in Urology” 5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.
37 citations
,
April 2008 in “The Cochrane library” 5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
17 citations
,
June 1996 in “The Journal of Steroid Biochemistry and Molecular Biology” FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
54 citations
,
May 2015 in “Endocrinology” Manipulating 5α-reductase type 2 can affect liver fat production and glucocorticoid effects.
153 citations
,
November 2004 in “Current Medicinal Chemistry” The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.
The treatment was not recommended due to limited effectiveness and significant side effects.